Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of March 2024

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

GSK plc

(the 'Company')

Publication of Annual Report 2023

The Company has today published on its website www.annualreport.gsk.com its Annual Report for the year ended 31 December 2023 ('Annual Report 2023').

In compliance with Listing Rule 9.6.1R of the UK Financial Conduct Authority ('FCA'), the Annual Report 2023 has been submitted to the FCA's National Storage Mechanism ('NSM') and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

A hard copy version of the Annual Report 2023 and the Notice of Annual General Meeting 2024 ('AGM Notice') will be sent to those shareholders who have elected to receive paper communications on or around 25 March 2024. The AGM Notice will be made available to shareholders who have not elected to receive paper communications on the same date.

This announcement is not a substitute for reading the Annual Report 2023 in full.

Additional Information

For the purposes of complying with the FCA's Disclosure and Transparency Rules ('DTRs') and the requirements imposed on issuers through the DTRs, information required to be communicated with the media in unedited full text was included in the Annual Report 2023. The Annual Report 2023 was submitted to the NSM and will shortly be available for inspection. It is also available on the Company's website as noted above.

This announcement is made in accordance with DTR 6.3.5R(1A).

V A Whyte

Company Secretary

1 March 2024

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

	GSK plc
	(Registrant)

Date: March 01, 2024

	By:/s/ VICTORIA WHYTE --------------------------

	Victoria Whyte
	Authorised Signatory for and on
	behalf of GSK plc